Form 4: Kiniksa Pharmaceuticals Executive Exercises Stock Options, Sells Shares
SEC Form 4 Filing
Chief Medical Officer John F. Paolini exercised stock options and sold shares of Kiniksa Pharmaceuticals International, plc on April 7, 2025.
Summary
- On April 7, 2025, John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, exercised restricted share units (RSUs) converting them into 2,498 Class A Ordinary Shares.
- Paolini also sold 734 Class A Ordinary Shares at a price of $20.28 per share to cover tax obligations.
- Following these transactions, Paolini directly owns 57,403 Class A Ordinary Shares and 2,497 Restricted Share Units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity.
Industry Context
This is a routine disclosure of insider transactions. It is common for executives to exercise stock options and sell a portion of the shares to cover taxes and diversify their holdings.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on shareholders, as it is a routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| April 7, 2022 | Date of grant for the Restricted Share Units (RSUs), which vest over a four-year period. |
| April 7, 2025 | Date of transaction: John F. Paolini exercised RSUs and sold Class A Ordinary Shares. |
| April 9, 2025 | Date of signature for the SEC Form 4 filing. |
Keywords
Kiniksa Pharmaceuticals, John F. Paolini, stock options, Class A Ordinary Shares, Restricted Share Units, SEC Form 4, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.